
  
    
      
        Introduction_NNP
        The_DT incidence_NN of_IN cholestasis_NNS related_VBN to_TO total_VB parenteral_NN
        nutrition_NN (_( TPN_NNP )_) among_IN preterm_NN infants_NNS has_VBZ been_VBN estimated_VBN to_TO
        be_VB between_IN 7_CD %_NN and_CC 85_CD %_NN ,_, depending_VBG on_IN the_DT population_NN examined_VBD
        and_CC the_DT definition_NN of_IN cholestasis_NNS used_VBD [_NN 1_CD ]_NN ._. In_IN infants_NNS
        with_IN necrotizing_VBG enterocolitis_NNS or_CC short_JJ bowel_NN syndrome_NN ,_, the_DT
        prevalence_NN of_IN TPN-related_NNP cholestasis_NNS is_VBZ 60_CD -_: 90_CD %_NN [_NN 2_CD ]_NN ._.
        Although_IN cholestasis_NNS is_VBZ reversible_JJ in_IN most_JJS patients_NNS after_IN
        the_DT successful_JJ advancement_NN of_IN enteral_NN feeding_NN ,_, progressive_JJ
        liver_NN fibrosis_NNS and_CC cirrhosis_NNS occur_VBP in_IN some_DT patients_NNS even_RB
        after_IN complete_JJ enteral_NN nutrition_NN has_VBZ been_VBN established_VBN [_NN 3_CD ]_NN ._.
        Some_DT studies_NNS have_VBP suggested_VBN that_IN excessive_JJ amino_JJ acids_NNS ,_,
        hepatotoxic_JJ bile_NN acids_NNS ,_, bacterial_JJ overgrowth_NN ,_, sepsis_NN ,_,
        micronutrient_NN deficiency_NN ,_, and_CC TPN_NNP contaminants_NNS all_DT
        contribute_VBP to_TO cholestatic_JJ liver_NN injury_NN [_NN 4_CD ,_, 5_CD ,_, 6_CD ]_NN ._.
        Diminished_NNP volume_NN of_IN enteral_NN feeds_VBZ may_MD also_RB independently_RB
        contribute_VB to_TO the_DT development_NN of_IN cholestasis_NNS ._. However_RB ,_, the_DT
        mechanisms_NNS of_IN liver_NN injury_NN in_IN cholestatic_JJ diseases_NNS in_IN
        infants_NNS remain_VBP unclear_JJ ._.
        Recent_JJ studies_NNS have_VBP supported_VBN the_DT hypothesis_NNS that_WDT
        generation_NN of_IN reactive_JJ oxygen_NN intermediates_NNS (_( ROIs_NNP )_) and_CC
        elevated_VBD lipid_NN hydroperoxides_NNS in_IN the_DT liver_NN during_IN
        cholestasis_NNS cause_VBP tissue_NN injury_NN ._. Exposure_NNP of_IN isolated_VBN
        hepatocytes_NNS to_TO hydrophobic_JJ bile_NN acids_NNS leads_VBZ to_TO
        intracellular_NN production_NN of_IN oxygen_NN free_JJ radicals_NNS and_CC lipid_NN
        peroxides_NNS [_NN 7_CD ]_NN ._. Animal_NNP studies_NNS using_VBG models_NNS of_IN surgically_RB
        induced_VBN extrahepatic_JJ biliary_JJ obstruction_NN have_VBP also_RB shown_VBN
        that_DT lipid_NN peroxidation_NN products_NNS -_: specifically_RB ,_,
        malondialdehyde_NN (_( MDA_NNP )_) -_: are_VBP increased_VBN in_IN the_DT cholestatic_JJ
        liver_NN [_NN 8_CD ,_, 9_CD ]_NN ._. This_DT increase_NN is_VBZ associated_VBN with_IN decreased_VBD
        tissue_NN antioxidant_NN activity_NN ,_, increased_VBN leukocyte_NN
        infiltration_NN ,_, and_CC early_JJ evidence_NN of_IN collagen_NN deposition_NN ;_:
        these_DT effects_NNS are_VBP ameliorated_JJ by_IN the_DT administration_NN of_IN
        exogenous_JJ antioxidants_NNS [_NN 8_CD ,_, 9_CD ,_, 10_CD ]_NN ._. Consistent_NNP with_IN these_DT
        findings_NNS ,_, several_JJ forms_NNS of_IN liver_NN disease_NN in_IN humans_NNS have_VBP
        been_VBN shown_VBN to_TO be_VB associated_VBN with_IN oxidative_JJ tissue_NN injury_NN ._.
        Specifically_RB ,_, products_NNS of_IN lipid_NN peroxidation_NN are_VBP elevated_VBD
        in_IN patients_NNS with_IN hepatic_JJ hypoxia_NN /_NN reperfusion_NN ,_, obstructive_JJ
        liver_NN disease_NN ,_, alcoholic_JJ liver_NN disease_NN ,_, Wilson_NNP 's_POS disease_NN ,_,
        Alagille_NNP syndrome_NN ,_, sepsis_NN ,_, and_CC inflammatory_JJ liver_NN diseases_NNS
        [_NN 11_CD ,_, 12_CD ,_, 13_CD ,_, 14_CD ,_, 15_CD ]_NN ._. 
        In_IN vitro_NN ,_, procollagen_NN gene_NN
        expression_NN increases_NNS in_IN human_JJ liver_NN cells_NNS after_IN exposure_NN to_TO
        lipid_NN peroxide_NN breakdown_NN products_NNS [_NN 16_CD ]_NN ._. Furthermore_RB ,_,
        deposition_NN of_IN lipofuscin_NN ,_, a_DT by-product_JJ of_IN lipid_NN
        peroxidation_NN ,_, characterizes_VBZ TPN-induced_NNP cholestasis_NNS in_IN
        preterm_NN infants_NNS [_NN 17_CD ]_NN ._.
        The_DT purpose_NN of_IN these_DT studies_NNS was_VBD to_TO determine_VB whether_IN
        TPN-induced_NNP cholestasis_NNS in_IN preterm_NN newborn_JJ infants_NNS is_VBZ
        associated_VBN with_IN increased_VBN oxidative_JJ stress_NN secondary_JJ to_TO
        increased_VB ROIs_NNP ._. We_PRP hypothesized_VBN that_DT elevation_NN in_IN markers_NNS
        of_IN oxidative_JJ stress_NN would_MD be_VB associated_VBN with_IN increased_VBN
        liver_NN injury_NN ,_, as_IN measured_VBN by_IN serum_NN alanine_NN transaminase_NN
        (_( ALT_NNP )_) and_CC aspartate_NN transaminase_NN (_( AST_NNP )_) levels_NNS ._. In_IN order_NN to_TO
        quantify_VB ROIs_NNP in_IN infants_NNS ,_, we_PRP measured_VBD urinary_JJ
        thiobarbituric-acid-reacting_JJ substances_NNS (_( TBARS_NNP )_) ._. The_DT most_RBS
        abundant_JJ of_IN these_DT substances_NNS is_VBZ MDA_NNP ,_, an_DT aldehydic_JJ lipid_NN
        peroxidation_NN product_NN formed_VBN by_IN the_DT action_NN of_IN ROIs_NNP on_IN lipid_NN
        membranes_NNS ._. The_DT identification_NN of_IN ROIs_NNP as_IN potential_JJ markers_NNS
        of_IN liver_NN injury_NN in_IN cholestatic_JJ preterm_NN infants_NNS may_MD aid_VB in_IN
        the_DT diagnosis_NN and_CC management_NN of_IN those_DT at_IN highest_JJS risk_NN for_IN
        ongoing_JJ liver_NN impairment_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Patients_NNS
          All_DT preterm_NN infants_NNS (_( <_NN 35_CD weeks_NNS '_POS gestation_NN )_) born_VBN at_IN
          St_NNP Peter_NNP 's_POS University_NNP Hospital_NNP (_( New_NNP Brunswick_NNP ,_, NJ_NNP ,_, USA_NNP )_)
          and_CC admitted_VBN to_TO the_DT hospital_NN 's_POS neonatal_NN intensive_JJ care_NN
          unit_NN between_IN March_NNP 1997_CD and_CC December_NNP 1998_CD were_VBD serially_RB
          screened_VBD during_IN the_DT course_NN of_IN hospitalization_NN for_IN entry_NN
          into_IN the_NNP '_POS cholestasis_NNS '_POS study_NN group_NN (_( Fig_NNP ._. 1_LS )_) ._. Infants_NNS with_IN
          major_JJ congenital_NN anomalies_NNS (_( including_VBG all_DT
          gastrointestinal_NN and_CC liver_NN anomalies_NNS )_) or_CC with_IN congenital_NN
          or_CC acquired_VBN infection_NN were_VBD excluded_VBN ._. The_DT criteria_NNS for_IN
          entry_NN into_IN the_DT cholestasis_NNS group_NN were_VBD direct_JJ bilirubin_NN
          >_NN 2_CD mg_NN /_NN dl_NN (_( 34_CD ._. 2_LS μmol_NN /_NN l_NN )_) and_CC duration_NN of_IN TPN_NNP ≥_NN 10_CD days_NNS ._.
          If_IN the_DT infant_NN met_VBD these_DT criteria_NNS ,_, the_DT parents_NNS '_POS informed_VBN
          consent_NN for_IN entry_NN into_IN the_DT study_NN was_VBD requested_VBN ._. During_IN
          this_DT period_NN ,_, 36_CD infants_NNS qualified_VBN for_IN the_DT cholestasis_NNS
          group_NN ,_, and_CC informed_VBD consent_NN was_VBD obtained_VBN from_IN the_DT parents_NNS
          of_IN 27_CD ._. When_WRB each_DT eligible_JJ infant_NN with_IN cholestasis_NNS was_VBD
          enrolled_VBN ,_, a_DT preterm_NN infant_NN without_IN cholestasis_NNS was_VBD
          matched_VBN for_IN gestational_JJ age_NN ,_, birth_NN weight_NN ,_, and_CC severity_NN
          of_IN respiratory_JJ illness_NN ,_, and_CC the_DT parents_NNS '_POS informed_VBN consent_NN
          was_VBD requested_VBN to_TO enroll_VB ,_, the_DT infant_NN as_IN a_DT control_NN subject_JJ ._.
          For_IN the_DT 27_CD infants_NNS enrolled_VBD in_IN the_DT cholestasis_NNS group_NN ,_,
          matched_VBN controls_NNS were_VBD identified_VBN for_IN 24_CD ._. Parental_JJ consent_NN
          could_MD not_RB be_VB obtained_VBN for_IN 8_CD ,_, so_RB 16_CD infants_NNS constituted_VBD
          the_DT control_NN group_NN ._. Study_NN personnel_NNS obtained_VBD demographic_JJ
          and_CC medical_JJ information_NN from_IN infants_NNS medical_JJ records_NNS ._.
        
        
          Determination_NNP of_IN urinary_JJ
          thiobarbituric-acid-reacting_JJ substances_NNS
          Urine_NNP samples_NNS were_VBD obtained_VBN under_IN sterile_JJ conditions_NNS
          from_IN all_DT enrolled_VBN infants_NNS at_IN the_DT time_NN of_IN their_PRP$ entry_NN into_IN
          the_DT study_NN ._. Informed_NNP consent_NN was_VBD obtained_VBN from_IN parents_NNS for_IN
          the_DT acquisition_NN of_IN samples_NNS ,_, and_CC these_DT studies_NNS were_VBD
          approved_VBN by_IN the_DT Committee_NNP for_IN the_DT Protection_NNP of_IN Human_NNP
          Subjects_NNP in_IN Research_NNP of_IN St_NNP Peter_NNP 's_POS University_NNP Hospital_NNP ._.
          TBARS_NNP were_VBD measured_VBN as_RB previously_RB described_VBD [_NN 18_CD ,_, 19_CD ]_NN ._.
          Briefly_NNP ,_, 200_CD μl_NN of_IN urine_NN was_VBD combined_VBN with_IN 10_CD μl_NN of_IN 5_CD %_NN
          butylated_JJ hydroxytoluene_NN (_( in_IN glacial_JJ acetic_JJ acid_NN )_) and_CC 300_CD
          l_NN of_IN a_DT 0_CD ._. 5_CD %_NN aqueous_JJ thiobarbituric_JJ acid_NN (_( TBA_NNP )_) solution_NN ._.
          The_DT samples_NNS were_VBD vortexed_JJ and_CC were_VBD incubated_JJ at_IN 100_CD °_NN C_NNP for_IN
          30_CD minutes_NNS ,_, and_CC the_DT absorbance_NN at_IN 532_CD nm_NN was_VBD measured_VBN
          using_VBG a_DT PerkinElmer_NNP Lamba_NNP 3_CD B_NNP spectrophotometer_NN
          (_( PerkinElmer_NNP ,_, Wellesley_NNP ,_, MA_NNP ,_, USA_NNP )_) ._. The_DT quantity_NN of_IN TBARS_NNP
          is_VBZ proportionate_NN to_TO the_DT amount_NN of_IN MDA_NNP ,_, a_DT lipid_NN
          peroxidation_NN product_NN generated_VBN by_IN the_DT oxidation_NN of_IN
          membrane_NN lipids_NNS by_IN reactive_JJ oxygen_NN species_NNS ._. MDA_NNP reacts_VBZ
          with_IN TBA_NNP to_TO form_VB a_DT 1_CD :_: 2_CD MDA-TBA_NNP adduct_NN that_WDT absorbs_VBZ at_IN 532_CD
          nm_NN ._. In_IN the_DT present_JJ studies_NNS ,_, MDA_NNP was_VBD confirmed_VBN to_TO be_VB the_DT
          predominant_NN TBA-reacting_NNP adduct_NN by_IN high-performance_JJ
          liquid_JJ chromatography_NN analysis_NN of_IN representative_NN samples_NNS ._.
          To_TO control_VB for_IN urine_NN concentration_NN ,_, data_NNS were_VBD normalized_JJ
          to_TO urine_NN creatinine_NN concentrations_NNS ,_, as_RB previously_RB
          described_VBD [_NN 20_CD ]_NN ._.
        
        
          Determination_NNP of_IN serum_NN bilirubin_NN ,_, ALT_NNP ,_, AST_NNP ,_,
          alkaline_NN phosphatase_NN
          Blood_NNP specimens_NNS were_VBD obtained_VBN from_IN subjects_NNS within_IN 24_CD
          hours_NNS of_IN the_DT urine_NN specimen_NN ._. Quantitative_NNP determinations_NNS
          of_IN serum_NN bilirubin_NN ,_, ALT_NNP ,_, AST_NNP ,_, and_CC alkaline_NN phosphatase_NN
          levels_NNS were_VBD performed_VBN by_IN the_DT clinical_JJ laboratory_NN at_IN St_NNP
          Peter_NNP 's_POS University_NNP Hospital_NNP ._.
        
        
          Statistical_NNP analysis_NN
          Direct_JJ bilirubin_NN ,_, ALT_NNP ,_, AST_NNP ,_, alkaline_NN phosphatase_NN ,_, and_CC
          urinary_JJ TBARS_NNP values_NNS were_VBD not_RB normally_RB distributed_VBN ._. The_DT
          data_NNS are_VBP presented_VBN as_IN median_JJ (_( 25_CD th_NN ,_, 75_CD th_NN percentile_NN )_) ._.
          Differences_NNS between_IN the_DT groups_NNS were_VBD analyzed_VBN for_IN
          significance_NN by_IN one-way_JJ ANOVA_NNP using_VBG natural_JJ log_NN
          transformations_NNS of_IN the_DT data_NNS ,_, which_WDT are_VBP normally_RB
          distributed_VBN ._. Differences_NNS were_VBD regarded_VBN as_RB statistically_RB
          significant_JJ at_IN 
          P_NN values_NNS ≤_NN 0_CD ._. 05_CD ._. Correlations_NNP of_IN
          bilirubin_NN ,_, ALT_NNP ,_, and_CC AST_NNP with_IN TBARS_NNP were_VBD calculated_VBN by_IN
          regression_NN using_VBG the_DT log-transformed_JJ values_NNS to_TO ensure_VB
          normal_JJ distribution_NN of_IN all_DT variables_NNS in_IN those_DT
          analyses_NNS ._.
        
      
      
        Results_NNS
        Twenty-seven_NNP infants_NNS were_VBD enrolled_VBN in_IN the_DT cholestasis_NNS
        group_NN and_CC 16_CD infants_NNS served_VBD as_IN controls_NNS ._. The_DT cholestasis_NNS
        and_CC control_NN groups_NNS were_VBD not_RB significantly_RB different_JJ with_IN
        respect_NN to_TO gestational_JJ age_NN (_( 29_CD ._. 3_LS ±_NN 4_CD ._. 7_CD vs_NNS 27_CD ._. 1_LS ±_NN 3_CD ._. 2_CD weeks_NNS ,_,
        respectively_RB )_) and_CC birth_NN weights_NNS (_( 1276_CD ±_NN 751_CD vs_NNS 1016_CD ±_NN 392_CD
        g_SYM )_) ,_, as_RB well_RB as_IN Apgar_NNP scores_NNS ,_, maximum_NN F_NNP 
        i_NNP O_NNP 
        2_CD ,_, and_CC length_NN of_IN time_NN for_IN which_WDT
        supplemental_JJ oxygen_NN was_VBD given_VBN (_( Table_NNP 1_LS )_) ._. Urine_NNP samples_NNS were_VBD
        collected_VBN at_IN 48_CD ._. 3_LS ±_NN 38_CD ._. 2_LS days_NNS of_IN age_NN in_IN the_DT cholestasis_NNS
        group_NN and_CC 38_CD ._. 4_LS ±_NN 22_CD ._. 1_LS days_NNS in_IN the_DT control_NN group_NN (_( 
        P_NN =_SYM 0_CD ._. 34_CD )_) ._. At_IN that_DT time_NN ,_, infants_NNS in_IN
        the_DT cholestasis_NNS group_NN had_VBD been_VBN advancing_VBG on_IN enteral_NN
        feedings_NNS in_IN addition_NN to_TO parenteral_NN nutrition_NN for_IN 11_CD ._. 3_LS ±_NN 5_CD ._. 5_CD
        days_NNS (_( range_NN 0_CD -_: 23_CD days_NNS )_) and_CC were_VBD receiving_VBG 21_CD ._. 4_LS ±_NN 12_CD ._. 3_LS ml_NN /_NN kg_NN
        per_IN day_NN enterally_RB ._. Control_NN infants_NNS were_VBD on_IN full_JJ enteral_NN
        feedings_NNS at_IN the_DT time_NN of_IN study_NN ._.
        Median_JJ serum_NN direct_JJ bilirubin_NN concentrations_NNS were_VBD 3_CD ._. 3_CD
        mg_NN /_NN dl_NN (_( 56_CD ._. 4_LS μmol_NN /_NN l_NN )_) in_IN the_DT cholestasis_NNS group_NN and_CC 1_CD ._. 7_CD mg_NN /_NN dl_NN
        (_( 29_CD ._. 1_LS μmol_NN /_NN l_NN )_) in_IN the_DT control_NN group_NN (_( 
        P_NN <_NN 0_CD ._. 001_CD )_) ._. Median_JJ serum_NN ALT_NNP and_CC
        AST_NNP levels_NNS were_VBD also_RB elevated_VBD in_IN the_DT cholestasis_NNS group_NN (_( 32_CD
        vs_NNS 9_CD and_CC 71_CD vs_NNS 33_CD U_NNP /_NN l_NN ,_, respectively_RB ;_: 
        P_NN <_NN 0_CD ._. 01_CD )_) ._. Values_NNP for_IN alkaline_NN
        phosphatase_NN and_CC mean_VB urinary_JJ TBARS_NNP did_VBD not_RB differ_VB
        significantly_RB between_IN the_DT groups_NNS (_( Table_NNP 2_LS )_) ._. Urinary_NNP TBARS_NNP
        were_VBD not_RB significantly_RB correlated_JJ with_IN gestational_JJ age_NN ,_,
        gender_NN ,_, days_NNS on_IN TPN_NNP ,_, indirect_JJ bilirubin_NN ,_, or_CC alkaline_NN
        phosphatase_NN (_( not_RB shown_VBN )_) ._. Likewise_RB ,_, urinary_JJ TBARS_NNP were_VBD not_RB
        correlated_JJ with_IN direct_JJ bilirubin_NN (_( Fig_NNP ._. 2_LS ,_, top_JJ )_) ._. In_IN
        contrast_NN ,_, urinary_JJ TBARS_NNP levels_NNS among_IN all_DT infants_NNS were_VBD
        independently_RB correlated_JJ with_IN serum_NN ALT_NNP and_CC AST_NNP (_( Fig_NNP ._. 2_LS ,_,
        lower_JJR )_) ._.
      
      
        Discussion_NNP
        We_PRP found_VBD that_WDT elevated_JJ liver_NN transaminases_NNS are_VBP
        associated_VBN with_IN increased_VBN oxidative_JJ stress_NN ._. These_DT findings_NNS
        suggest_VBP that_DT oxidant_NN stress_NN (_( as_IN indicated_VBN by_IN elevated_VBD
        TBARS_NNP )_) is_VBZ associated_VBN with_IN hepatocellular_NN injury_NN in_IN preterm_NN
        infants_NNS ._. Although_IN there_EX is_VBZ ample_JJ evidence_NN that_DT oxidant_NN
        stress_NN follows_VBZ cholestasis_NNS ,_, our_PRP$ findings_NNS suggest_VBP that_IN
        oxidative_JJ injury_NN in_IN the_DT liver_NN may_MD be_VB induced_VBN by_IN mechanisms_NNS
        that_WDT are_VBP independent_JJ of_IN cholestasis_NNS [_NN 7_CD ,_, 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. For_IN
        example_NN ,_, the_DT production_NN of_IN ROIs_NNP in_IN the_DT liver_NN may_MD be_VB linked_VBN
        to_TO inflammation_NN ,_, which_WDT has_VBZ emerged_VBN as_IN a_DT primary_JJ mechanism_NN
        of_IN liver_NN injury_NN after_IN pathophysiological_JJ insults_NNS ._. Activated_NNP
        Kupffer_NNP cells_NNS and_CC neutrophils_NNS release_VBP ROIs_NNP and_CC proteases_NNS in_IN
        response_NN to_TO inflammatory_JJ cytokines_NNS in_IN the_DT liver_NN [_NN 21_CD ]_NN ._. ROIs_NNP
        in_IN excess_JJ inactivate_NN proteins_NNS ,_, disrupt_VB DNA_NNP ,_, and_CC oxidize_NN
        lipids_NNS [_NN 22_CD ]_NN ._. Preterm_NNP newborn_JJ infants_NNS may_MD be_VB particularly_RB
        susceptible_JJ to_TO such_JJ injury_NN because_IN they_PRP exhibit_NN an_DT
        imbalance_NN between_IN antioxidant-_NN and_CC oxidant-generating_JJ
        systems_NNS ._. For_IN example_NN ,_, such_JJ infants_NNS exhibit_NN decreased_VBD levels_NNS
        in_IN the_DT liver_NN of_IN superoxide_NN dismutase_NN ,_, vitamin_NN E_NNP ,_, and_CC
        β-carotene_JJ [_NN 23_CD ,_, 24_CD ,_, 25_CD ]_NN ._. Antioxidant_NNP capacity_NN in_IN preterm_NN
        infants_NNS is_VBZ also_RB compromised_VBN by_IN relative_JJ deficiencies_NNS of_IN
        selenium_NN and_CC taurine_NN ,_, as_RB well_RB as_IN reduced_VBN ability_NN to_TO
        synthesize_VB sufficient_JJ glutathione_NN [_NN 26_CD ]_NN ._.
        Despite_IN longer_JJR TPN_NNP courses_NNS and_CC elevated_VBD serum_NN
        transaminases_NNS ,_, infants_NNS with_IN cholestasis_NNS or_CC elevated_VBD serum_NN
        direct_JJ bilirubin_NN did_VBD not_RB display_NN elevated_VBD urinary_JJ TBARS_NNP ._.
        Our_PRP$ findings_NNS are_VBP consistent_JJ with_IN previous_JJ reports_NNS
        indicating_VBG an_DT inconsistent_JJ relation_NN between_IN bilirubin_NN
        levels_NNS and_CC the_DT degree_NN of_IN histologic_JJ liver_NN injury_NN [_NN 27_CD ,_, 28_CD ]_NN ._.
        This_DT inconsistency_NN suggests_VBZ that_IN cholestasis_NNS and_CC hepatic_JJ
        impairment_NN in_IN preterm_NN infants_NNS receiving_VBG TPN_NNP are_VBP induced_VBN by_IN
        mechanisms_NNS that_WDT are_VBP not_RB dependent_JJ on_IN oxidant-mediated_JJ
        hepatocellular_NN injury_NN ._. For_IN example_NN ,_, lack_NN of_IN enteral_NN feeding_NN
        plays_VBZ an_DT important_JJ role_NN in_IN the_DT development_NN of_IN cholestasis_NNS
        in_IN the_DT neonatal_NN period_NN ,_, possibly_RB mediated_JJ by_IN direct_JJ
        hepatotoxic_JJ activity_NN of_IN bile_NN salts_NNS [_NN 5_CD ]_NN ._. Bile_NNP salts_NNS are_VBP
        thought_VBN to_TO exert_VB adverse_JJ effects_NNS on_IN signal_NN transduction_NN and_CC
        gene_NN transcription_NN in_IN hepatocytes_NNS and_CC cholangiocytes_NNS and_CC to_TO
        activate_VBP Fas-induced_NNP apoptosis_NNS [_NN 21_CD ]_NN ._. TPN-induced_NNP
        cholestasis_NNS in_IN infants_NNS also_RB appears_VBZ to_TO be_VB related_VBN directly_RB
        to_TO developmental_NN immaturity_NN of_IN bile_NN flow_NN and_CC production_NN and_CC
        to_TO possible_JJ infection_NN [_NN 29_CD ]_NN ._.
        TBARS_NNP measurements_NNS provide_VBP a_DT measure_NN of_IN membrane_NN lipid_NN
        peroxidation_NN and_CC ,_, as_IN such_JJ ,_, may_MD provide_VB a_DT direct_JJ assessment_NN
        of_IN the_DT progression_NN of_IN liver_NN injury_NN at_IN the_DT cellular_JJ level_NN ._.
        Although_IN there_EX was_VBD a_DT statistically_RB significant_JJ relationship_NN
        between_IN urinary_JJ TBARS_NNP and_CC liver_NN transaminases_NNS ,_, a_DT large_JJ
        degree_NN of_IN overlap_VB existed_VBN between_IN the_DT groups_NNS ._. Furthermore_RB ,_,
        the_DT association_NN between_IN TBARS_NNP levels_NNS and_CC liver_NN injury_NN does_VBZ
        not_RB necessarily_RB indicate_VB causality_NN ._. Despite_IN physiologic_JJ
        evidence_NN that_IN ROIs_NNP play_VB a_DT central_JJ role_NN in_IN tissue_NN injury_NN
        during_IN inflammation_NN ,_, it_PRP is_VBZ possible_JJ that_WDT elevated_VBD TBARS_NNP
        occur_VB secondary_JJ to_TO other_JJ mechanisms_NNS of_IN hepatocellular_NN
        injury_NN [_NN 30_CD ,_, 31_CD ]_NN ._. Larger_NNP longitudinal_NN and_CC /_NN or_CC interventional_NN
        (_( e_SYM ._. g_SYM ._. antioxidant_NN administration_NN )_) studies_NNS will_MD be_VB necessary_JJ
        to_TO determine_VB whether_IN there_EX is_VBZ a_DT causal_NN relationship_NN between_IN
        lipid_NN peroxidation_NN and_CC TPN-induced_NNP liver_NN disease_NN in_IN preterm_NN
        infants_NNS ._.
      
      
        Key_JJ messages_NNS
        •_NN Serum_NNP transaminases_NNS are_VBP elevated_VBD in_IN preterm_NN infants_NNS
        (_( <_NN 35_CD weeks_NNS '_POS gestational_JJ age_NN )_) with_IN cholestasis_NNS and_CC
        prolonged_JJ administration_NN of_IN total_JJ parenteral_NN nutrition_NN
        (_( TPN_NNP )_) ,_, indicating_VBG that_IN cholestasis_NNS is_VBZ associated_VBN with_IN
        hepatocellular_NN injury_NN
        •_NN Urinary_NNP levels_NNS of_IN thiobarbituric-acid-reacting_JJ
        substances_NNS (_( TBARS_NNP )_) ,_, which_WDT are_VBP proportional_JJ to_TO lipid_NN
        peroxidation_NN and_CC oxidant_NN stress_NN ,_, are_VBP correlated_JJ with_IN serum_NN
        transaminase_NN levels_NNS ._. Our_PRP$ findings_NNS suggest_VBP that_DT oxidant_NN
        stress_NN is_VBZ associated_VBN with_IN hepatocellular_NN injury_NN in_IN preterm_NN
        infants_NNS
        •_NN Urinary_NNP levels_NNS of_IN TBARS_NNP do_VBP not_RB differ_VB significantly_RB
        between_IN infants_NNS with_IN cholestasis_NNS and_CC control_NN infants_NNS
        •_NN Our_PRP$ findings_NNS suggest_VBP that_IN cholestasis_NNS in_IN preterm_NN
        infants_NNS receiving_VBG TPN_NNP is_VBZ induced_VBN ,_, in_IN large_JJ part_NN ,_, by_IN
        mechanisms_NNS that_WDT are_VBP not_RB dependent_JJ on_IN oxidant-mediated_JJ
        hepatocellular_NN injury_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        ALT_NNP =_SYM alanine_NN transaminase_NN ;_: AST_NNP =_SYM aspartate_NN
        transaminase_NN ;_: MDA_NNP =_SYM malondialdehyde_NN ;_: ROIs_NNP =_SYM reactive_JJ oxygen_NN
        intermediates_NNS ;_: TBA_NNP =_SYM thiobarbituric_JJ acid_NN ;_: TBARS_NNP =_SYM
        thiobarbituric-acid-reacting_JJ substances_NNS ;_: TPN_NNP =_SYM total_JJ
        parenteral_NN nutrition_NN ._.
      
    
  
